<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967171</url>
  </required_header>
  <id_info>
    <org_study_id>BezmialemVU Oxytocin effect</org_study_id>
    <nct_id>NCT03967171</nct_id>
  </id_info>
  <brief_title>The Comparison of the Effect of Different Oxytocin Administrations on the Blood Loss During Cesarean Delivery</brief_title>
  <official_title>The Comparison of the Effect of Different Oxytocin Administrations on the Blood Loss During Cesarean Delivery: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of starting intravenous oxytocin infusion early before uterine
      incision versus late after umbilical cord clamping on the blood loss during elective cesarean
      section
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum hemorrhage (PPH) is still the major cause of maternal morbidity and mortality
      worldwide contributing to nearly 25% of direct maternal deaths. The average blood loss during
      cesarean section is 1000 ml which is nearly double the blood loss during vaginal delivery.
      Worldwide, the most commonly used uterotonic for the prevention of PPH is oxytocin. Several
      regimens of oxytocin have been tested during cesarean section with variable wanted
      (uterotonic) and unwanted (cardiovascular) effects. In the current study, we tested the
      hypothesis that initiating IV oxytocin infusion earlier before uterine incision would induce
      a rapid acceptable uterine contraction and minimize the intraoperative blood loss than the
      same dose administered after delivery of the fetus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood loss during elective cesarean section</measure>
    <time_frame>2 hours</time_frame>
    <description>The intraoperative blood loss will be measured by adding the volume of the suction bottle with the blood soaked sponges (know dry weight). The blood loss was estimated after excluded amniotic fluid volume in the suction bottle in each case</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative blood loss</measure>
    <time_frame>24 hours</time_frame>
    <description>The hemoglobin and hematocrit values will be measured 24 hours after CS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>postoperative pain score</measure>
    <time_frame>24 hours</time_frame>
    <description>The Visual Analogue Scale (VAS) will be implemented postoperative day 0 and postoperative 1st day</description>
  </other_outcome>
  <other_outcome>
    <measure>neonatal wellbeing</measure>
    <time_frame>2 hours</time_frame>
    <description>Apgar scores (1 and 5 minutes) will be compared</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Cesarean Section Complications</condition>
  <condition>Postpartum Hemorrhage</condition>
  <condition>Blood Loss, Surgical</condition>
  <condition>Blood Loss, Postoperative</condition>
  <condition>Postoperative Pain</condition>
  <condition>Atony, Uterine</condition>
  <arm_group>
    <arm_group_label>before uterine incision oxytocin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of 20 IU of oxytocin started before uterine incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>after clamping the umbilical cord oxytocin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV infusion of 20 IU of oxytocin started immediately after clamping the umbilical cord</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>before uterine incision oxytocin</intervention_name>
    <description>blood loss during elective cesarean section</description>
    <arm_group_label>before uterine incision oxytocin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>after clamping the umbilical cord oxytocin</intervention_name>
    <description>blood loss during elective cesarean section</description>
    <arm_group_label>after clamping the umbilical cord oxytocin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  single fetus at term &gt;37 weeks of gestational age

        Exclusion Criteria:

          -  history of previous cesarean section

          -  history of previous uterine surgery

          -  multiple gestation, placenta previa, polyhydramnious, fetal macrosomia

          -  women at high risk for uterine atony such as anemia (Hb &lt; 8 gm/dL)

          -  uterine atony history

          -  gestational diabetes mellitus, gestational hypertension, preeclampsia, current or
             previous history of heart disease, liver, renal disorders or known coagulopath
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bezmialem VakÄ±f University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>cesarean section</keyword>
  <keyword>uterine atony</keyword>
  <keyword>Postpartum Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Uterine Inertia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

